Auris is a technology company dedicated to improving healthcare for all patients who need medical intervention. We believe that healthcare is a sacred right of all individuals and that each human deserves the most effective care possible.
Over the past 50 years, the introduction of new technologies has ushered in the era of minimally invasive techniques and procedures. Recent advancements in surgical instrumentation and imaging have improved patient outcomes, shortened recovery times, and lowered overall expenses.
Auris will dramatically accelerate the development of less invasive intervention by allowing precision and consistency of care across each treatment. We are developing targeted, minimally invasive therapies that treat only the diseased cells in order to prevent the progression of a patient’s illness. Our technology uses a patient-specific approach that maintains the integrity of the human body and its organ systems during medical intervention.
Our platform integrates the latest advancements in robotics, micro-instrumentation, sensing, and data science to achieve these breakthroughs and deliver dramatically improved clinical outcomes for patients.
Auris is committed to tackling some of the biggest problems in healthcare. We are developing solutions for a multitude of disease states where the standard treatments are inconsistent and sub-optimal.
Lung cancer is the first disease in our sights.
There are 1 billion smokers worldwide creating an epidemic of 6 million deaths per year. More patients die every year from lung cancer than from prostate, breast and colon cancer combined.
The reason lung cancer is so deadly is that the diagnostic and treatment processes are ineffective. The majority of lung cancer patients are diagnosed in late stage, when the cancer has already spread beyond its primary location. With our technology, physicians will be able to access early stage lung cancer without incisions, allowing accurate diagnosis and targeted treatment.
We are honored to have the support of leading global investors, including early backers Mithril, Lux Capital and Highland Capital Partners. We would like also to welcome Coatue Management LLC as the lead of our Series D financing, which totaled $280 million. Additional Series D investors included Viking Global Investors, Section 32 and Partner Fund Management.
Ten years from now, someone you know and love, a brother, a friend, will walk into the hospital with what today we consider a fatal disease. Later that afternoon, she will go home, cured. No one will call it a miracle. Just the reality of modern healthcare.
This is the future Auris will help create.
Frederic H. Moll, M.D. is the co-founder and CEO of Auris Surgical Robotics. Prior to Auris, Dr. Moll co-Founded Hansen Medical and served as the company's Chief Executive Officer from 2002 - 2010. Previously, Dr. Moll Co-founded Intuitive Surgical Inc., a medical device company, and served as its first Chief Executive Officer and later, its Vice President and Medical Director. Dr. Moll Co-founded Origin Medsystems, Inc., a medical device company, which later became an operating company within Guidant Corporation, a medical device company, following its acquisition by Eli Lilly in 1992. Dr. Moll served as Medical Director of Guidant's Surgical Device Division until November 1995.
Ajay co-founded Mithril in 2012 and leads the firm as its Managing General Partner. He was formerly Managing Director and Senior Investor at Clarium, where he led unlevered growth investments. He co-founded Breakout Labs, has been a recurring guest lecturer on macro investing at Yale, and serves as an external adviser to Oak Ridge National Laboratory and the University of Michigan Risk Science Center. He earned a B.A. from Yale.
Peter is co-founder of Lux Capital and focuses on investments in technology and energy. Peter began his career at Lehman Brothers, where he worked in the firm's top-ranked Equity Research group. In 2000, he co-founded Lux Capital. In 2003, Peter led the spin-off of Lux Research. As founding CEO, he helped build Lux Research into the leading emerging technology research firm.
Dr. Salehizadeh has over 15 years of healthcare operating and investment experience. Prior to co-founding NaviMed Capital, he was a General Partner at Highland Capital Partners, where he focused on growth stage healthcare investments. Prior to joining Highland Capital Partners in 2003, Dr. Salehizadeh spent several years in a variety of operational roles at Medtronic. Before Medtronic, Dr. Salehizadeh held a variety of senior management roles with HealthCentral, a private equity-backed digital health company that went public in 1999. Dr. Salehizadeh holds an AB in Molecular Biology from Princeton University, an MD and Master’s in Science in Health Policy from Columbia University, and an MBA from Harvard Business School. He is also a graduate of the Kauffman Fellows Program.
Bob Kerrey is Managing Director at Allen & Company. He is also a former governor, senator and education leader and serves as Executive Chairman of the Minerva Institute for Research and Scholarship, supporting The Minerva Project, an exceptional liberal arts and sciences education. From 1983 to 1987, Kerry served a single term as Nebraska’s governor, and later represented Nebraska in the U.S. Senate from 1989 to 2001. Kerrey was a candidate for the Democratic presidential nomination in 1992. Before entering politics, he served in the Vietnam War as a Navy SEAL officer and was awarded the Congressional Medal of Honor for heroism in combat.
Send us your name, email address and a text version of your resume.
Auris Surgical Robotics Inc.
150 Shoreline Dr.
Redwood City, CA 94065
Tel: (650) 610-0750